Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to $10.6 million.

  • Oncology Institute's Cash from Financing Activities rose 446213.99% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 17226.91%. This contributed to the annual value of -$3.5 million for FY2024, which is 4899.96% up from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Cash from Financing Activities is $10.6 million, which was up 446213.99% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Cash from Financing Activities ranged from a high of $136.1 million in Q4 2021 and a low of -$10.7 million during Q2 2022
  • Its 5-year average for Cash from Financing Activities is $12.8 million, with a median of -$847000.0 in 2022.
  • As far as peak fluctuations go, Oncology Institute's Cash from Financing Activities crashed by 29060967.74% in 2021, and later surged by 131753750.0% in 2022.
  • Oncology Institute's Cash from Financing Activities (Quarter) stood at $136.1 million in 2021, then plummeted by 100.62% to -$847000.0 in 2022, then tumbled by 110.27% to -$1.8 million in 2023, then skyrocketed by 90.79% to -$164000.0 in 2024, then skyrocketed by 6563.41% to $10.6 million in 2025.
  • Its last three reported values are $10.6 million in Q3 2025, $2.0 million for Q2 2025, and -$4.7 million during Q1 2025.